REGENXBIO (RGNX) Scheduled to Post Earnings on Wednesday

REGENXBIO (NASDAQ:RGNX) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

REGENXBIO Stock Performance

RGNX traded up $0.05 during midday trading on Tuesday, hitting $8.81. The company had a trading volume of 140,192 shares, compared to its average volume of 589,602. REGENXBIO has a twelve month low of $8.53 and a twelve month high of $28.80. The company has a market capitalization of $435.42 million, a PE ratio of -1.65 and a beta of 1.23. The firm’s 50-day simple moving average is $10.72 and its 200-day simple moving average is $12.60.

Insider Transactions at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.56, for a total value of $115,600.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at $130,466.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 13.13% of the company’s stock.

Wall Street Analysts Forecast Growth

RGNX has been the topic of several research reports. Raymond James reaffirmed an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Barclays cut their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. HC Wainwright reissued a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a research note on Wednesday, September 4th. Finally, Chardan Capital restated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Tuesday, October 22nd. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.45.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.